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Isoniazid preventive treatment among child contacts of adults 
with smear-positive tuberculosis in The Gambia
U. Egere,1 A. Sillah,1 T. Togun,1,2 S. Kandeh,1 F. Cole,1 A. Jallow,3 A. Able-Thomas,3 M. Hoelscher,4  
N. Heinrich,4 P. C. Hill,5 B. Kampmann1,6
The current elimination goals for tuberculosis (TB) include a focus on individuals who are latently 
infected with Mycobacterium tuberculosis to reduce the 
number of new TB cases and subsequent M. tuberculo-
sis transmission.1 This strategy requires isoniazid pre-
ventive therapy (IPT) or an alternative regimen. Initial 
targets are those at most risk of disease progression, 
such as young children and human immunodefi-
ciency virus (HIV) infected individuals in contact with 
an infectious adult with TB.2
The above World Health Organization (WHO) rec-
ommendations have not, however, been implemented 
in most of the high-burden TB settings where IPT is 
most needed. In many places where IPT has been im-
plemented and evaluated, the impact is suboptimal 
and the operational challenges are formidable.3–6 Con-
sidering the cascade of care as a whole, it is estimated 
that, even where IPT is part of routine practice, only a 
minority of eligible children complete a course of 
treatment.7 Not only is uptake poor, but adherence 
rates tend to be less than 30% among those who do 
commence IPT.8,9 The measurement of adherence can 
also be unreliable, relying heavily on reports from care 
givers, how often care givers return for more medica-
tion, and pill counts.10,11 Furthermore, interventions 
to improve IPT delivery frequently do not result in im-
proved uptake, adherence and treatment comple-
tion.12 A recent meta-analysis of the cascade of care for 
treatment of latent tuberculous infection (LTBI), 
which indicated where patients get lost in the system 
for various reasons, focused primarily on adults.13
As IPT implementation now has a higher priority 
within the agenda for TB control,14 and as implemen-
tation via TB clinics appears to be challenging, we de-
veloped a home-based IPT programme among child 
contacts of recently diagnosed adult sputum 
smear-positive TB cases and assessed its impact on up-
take, completion and adherence within the cascade of 
care in The Gambia. We also measured the isoniazid 
(INH) metabolites in urine to assess the reliability of 
our adherence measures.
METHODS
Study sites
The study was carried out in the Greater Banjul area of 
The Gambia between November 2013 and May 2015. 
This is a mixed urban-to-rural area, including the capi-
tal city of Banjul, and has a population of approxi-
mately 700 000. The setting has been described 
elsewhere.15
Participants
Child contacts aged 5 years living in the same 
household as adult sputum smear-positive TB cases 
were recruited. A household was defined as a group of 
individuals eating from the same pot and living in the 
same building.16
Symptom screening, tuberculin skin testing and 
clinical evaluation
Adults with newly diagnosed sputum smear-positive 
TB were identified at the National Leprosy/TB Control 
Programme (NLTP) clinics and were asked for their 
consent to a household visit. After the project was ex-
plained to the parents/care givers, written informed 
consent was obtained. A standard symptom-screening 
questionnaire for TB was then administered to ascer-
tain if any child living in the same household had a 
cough of 2 weeks’ duration in association with at 
least one of the following symptoms: weight loss, fail-
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Setting: Greater Banjul area of The Gambia.
Objectives: To evaluate uptake, adherence and comple-
tion of treatment among tuberculosis (TB) exposed chil-
dren in The Gambia when isoniazid preventive treatment 
(IPT) is delivered at home
Design: Child (age 5 years) contacts of adults with 
smear-positive TB were prospectively enrolled. Following 
symptom screening, tuberculin skin testing and clinical 
evaluation where indicated, those without disease were 
placed on daily isoniazid, provided monthly at home. Ad-
herence was assessed by pill counts and IsoScreen™ 
urine test.
Results: Of 404 contacts aged 5 years, 368 (91.1%) 
were offered IPT. Of the 328 (89.4%) for whom consent 
was received and who commenced IPT, 18 (5.5%) 
dropped out and 310 (94.5%) remained on IPT to the 
end of the 6-month regimen. Altogether, 255/328 chil-
dren (77.7%, 95%CI 73.2–82.2) completed all 6 months, 
with good adherence. The IsoScreen test was positive in 
85.3% (435/510) of all tests among those defined as hav-
ing good adherence by pill count and in 16% (8/50) of 
those defined as having poor adherence (P  0.001). A 
cascade of care analysis showed an overall completion 
rate with good adherence of 61% for all child contacts.
Conclusion: Home-delivered IPT among child contacts 
of adults with smear-positive TB in The Gambia achieved 
verifiable high uptake and adherence rates. System rather 
than patient factors are likely to determine the success of 
IPT at national level.
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ure to gain weight, fever or night sweats. The tubercu-
lin skin test (TST) was performed using the Mantoux 
method (2 tuberculin units of purified protein deriva-
tive RT23, Statens Serum Institute, Copenhagen, Den-
mark) and read 48–72 h later. A positive TST was de-
fined as an induration of 10 mm, in line with WHO 
recommendations.17 Child contacts with symptoms 
suggestive of TB and/or a positive TST were referred to 
a dedicated childhood TB clinic for further evaluation. 
All children diagnosed with TB disease were referred to 
the TB clinics of the NLTP for DOTS-based treatment.
Isoniazid prophylaxis and follow-up
All child household contacts aged 5 years in whom 
TB disease was excluded were provided with IPT at 10 
mg/kg/day for 6 months, as recommended by the 
WHO,2 regardless of their TST result. Field workers de-
livered the IPT to the homes of the children on a 
monthly basis and administered a brief questionnaire 
to capture missed doses, the reasons for missed doses 
and any adverse events from the medication. To mea-
sure adherence, pill counts were performed for all chil-
dren. An IPT card was specifically developed to record 
the child’s weight and the number of unconsumed 
doses of medication. All children were assessed every 3 
months for 1 year; those with new symptoms sugges-
tive of TB were referred to the childhood TB clinic at 
the Medical Research Council (MRC) unit. A final 
home visit was made 1 year after INH completion to 
ascertain post-IPT status.
IsoScreen testing
In the first year of the study, consecutively recruited 
children on IPT were asked to provide a monthly urine 
sample for a qualitative assessment of adherence using 
the IsoScreenTM test (GFC Diagnostics Ltd, Oxford-
shire, UK), a point-of-care colorimetric assay that de-
tects INH and its metabolites utilising a disposable 
plastic test device and the Arkansas method for metab-
olite detection.18 Two ml of collected urine was in-
jected into a reaction chamber and mixed with the re-
agents contained in an effervescent tablet for about 
10 s. Dark blue/purple colouration appearing within 5 
min indicates a positive result, i.e., the individual has 
taken INH within the previous 24–48 h. If no INH has 
been taken, the colour of the urine remains un-
changed, indicating a negative result. Care givers were 
informed about the monthly visits, but the actual days 
of the visit were unannounced. The results of the Iso-
Screen testing were recorded on the child’s INH card.
Ethics approval
Ethics approval for the study was obtained from the 
joint Medical Research Council/Gambian government 
ethics committee (Ref. L2012.E01), Banjul, The 
Gambia.
Data analysis
Data were double-entered into an Access database (Mi-
crosoft Corp, Redmond, WA, USA) and verified using 
consistency checks. All analyses were performed using 
STATA/IC 13.1 (StataCorp, College Station, TX, USA). 
IPT implementation was assessed using a cascade of 
care approach. To provide a denominator for the up-
take component of the cascade, the number of con-
tacts of those TB cases who refused a home visit and 
the number of children with TB disease among those 
who had not been assessed in the clinic were esti-
mated. This was performed by simple extrapolation of 
the average number of child contacts per case and the 
rate of disease in those assessed to a rate of disease in 
those not assessed, rounded to the nearest whole num-
ber.13 Adherence was divided into three categories: 
good, reasonable and poor, if respectively 80%, 60–
80% or 60% of the pills delivered each month had 
been taken.19 Treatment completion was defined as 
consuming 80% of all pills prescribed in each of the 
6 months of prophylaxis.20 The proportion of children 
with a positive IsoScreen test result was compared 
among the adherence categories using the χ2 test. The 
data are presented in frequencies, proportions and per-
centages with their 95% confidence interval (CI).
RESULTS
IPT uptake and characteristics of those 
commenced on IPT
Over the study period, 301/330 adults with sputum 
smear-positive TB consented to contact tracing in their 
households. Altogether 404 children aged 5 years 
and living in the same household as an adult index 
case were screened at community level. Of these, 163 
symptomatic and/or TST-positive children were re-
ferred for further evaluation in the clinic, and 153/163 
(94%) attended the appointment. Of this group, 26 
(16.9%) were diagnosed with active TB. The remaining 
368 children were eligible for IPT and consent was 
sought from their parent or legal guardian, of whom 
25 refused, 14 moved out of the study area after con-
senting and one child died of a brief febrile illness 
thought to be malaria in the first month of prophy-
laxis (Figure 1). Of 328 children initiated on IPT, 50.6% 
were females; the median age (interquartile range 
[IQR]) at recruitment was 2.3 years (IQR 1.3–3.4) 
(Table 1).
Completion of IPT
Of the 328 children commenced on IPT, 318 (96.9%) 
started within 1 month of the diagnosis of their re-
spective index cases. IPT was administered by the 
mothers in 92.3% (303/328) of the cases, by the fa-
thers in 2.4% (8/325), and by grandmothers and sib-
lings in 0.9% of cases each.
Eighteen of the 328 children dropped out of IPT, 
leaving 310 children remaining on prophylaxis at the 
end of 6 months. There was no difference in the char-
acteristics of those who dropped out and those who 
completed prophylaxis. A final 255 of the 328 children 
(77.7%, 95%CI 73.2–82.2) completed the 6 months of 
IPT with good adherence.
Adherence to treatment
During the study period, 59 040 doses of IPT were dis-
pensed, of which 53 573 (90.7%) were consumed. 
Based on pill counts, 78.9% (95%CI 74.5–83.2) of all 
medications were consumed by children with good ad-
herence, 15.4% (95%CI 11.5–19.3) by children with 
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reasonable adherence, and 5.6% (95%CI 3.1–8.1) by children with 
poor adherence. Table 2 shows the monthly adherence of chil-
dren on IPT as determined by pill count. Less than 10% of chil-
dren on prophylaxis in any month had poor adherence. Overall, 
the proportion of children with positive IsoScreen test results was 
similar to the proportion with good adherence: good adherence 
by pill count was 77.4% (95%CI 74.2–80.6) compared to 76.6% 
(95%CI 73.4–79.8) with positive urine test results.
The proportion of children with good adherence remained 
high, at 76.2% in the first month, and increased gradually over 
time to 83% in month 6. Spot urine samples were collected from 
the first 141 children recruited into the study, and 658 episodes of 
pill counts and urine tests were carried out simultaneously. 
Among these children, 85.3% (435/510) of all tests among those 
defined as having good adherence by pill count were positive, 
compared to 16% (8/50) of tests among those defined as having 
poor adherence (P  0.001). Over the 6 months of IPT, 80.6–
93.3% of those with good adherence by pill count were also posi-
tive by IsoScreen, compared to 0–25.0% of those with poor adher-
ence (Table 3). Across the three adherence categories there was a 
significant trend in IsoScreen positivity (P  0.002) in each 
month of IPT. 
Of 314 responses to the adherence questionnaire adminis-
tered among care givers, 247 (78.7%) stated that the main reason 
for failure to administer the pills was forgetfulness. The second 
major reason, given by 30 (9.6%) of the care givers, was travel. 
Other reasons included the child being sick (11 [3.5%]), refusing 
medication (7 [2.2%]) and misplacement of the medications (5 
[1.6%]).
Side effects
No side effects were reported throughout the study period.
One-year follow-up
Of the 310 children who completed their course of IPT, 12 (3.9%) 
were lost to follow-up at 1 year after IPT. One child aged 18 
months died of a sudden febrile illness not related to INH or TB. 
One child who dropped out of IPT in the first month developed 
clinically diagnosed TB by the ninth month of follow-up. All the 
other children remained well.
Cascade of care summary analysis
To identify where improvements may be needed in the contin-
uum of care of child contacts eligible for IPT, we used a cascade of 
care approach, as summarised in Figure 2. We estimated uptake 
and completion of IPT among all eligible children in the house-
holds of the 330 adults with TB approached during the study. Af-
ter excluding 27 children with TB disease (26 diagnosed after clin-
ical evaluation and one estimated from among those who failed 
to attend the clinic), 418 children remained eligible for IPT, of 
whom 328 (78.5%) accepted IPT and 255 (61%) completed 6 
months of IPT with good adherence.
DISCUSSION
In this study, we implemented and evaluated a home-based IPT 
programme in The Gambia. Uptake of IPT was high (78%), and 
77.7% of all child contacts who initiated IPT completed the 
6-month course with good adherence. A further 15.4% had rea-
sonable adherence, and 5.6% had poor adherence. We also found 
that pill count reliably reflected adherence in this population. 
The most frequent reason for non-adherence was forgetfulness. 
The cascade of care analysis showed that approximately 61% of 
the estimated original number of contacts eligible for IPT com-
pleted 6 months of IPT with good adherence, and provides in-
sight into the potential public health impact of the programme.
Adherence is a major determinant of efficacy of IPT.21 High IPT 
uptake in The Gambia is encouraging as the country moves to ex-
pand these services nationwide. In high TB burden countries, the 
proportion of those commencing and completing at least 4 
months of IPT is approximately 15%,6,7 and even in research con-
ditions adherence to unsupervised IPT in high-burden countries 
has been relatively low. Good adherence to IPT was achieved by 
approximately 24% in South Africa,4,22 25.6% in Indonesia8 and 
32.5% in Southern Ethiopia.9 In contrast, in another research 
study conducted in Guinea Bissau, West Africa, where IPT was 
also delivered to the homes of child contacts for 9 months, the 
proportion achieving good adherence according to pill counts 
was 76%,20 similar to our study. Interestingly, when INH was de-
livered at home to children in Ethiopia, adherence was very poor, 
with only 33% of children taking their medications for up to 4 
FIGURE 1 Flow chart of screening and recruitment of children on 
INH prophylaxis. INH = isoniazid; TB = tuberculosis.
TABLE 1 Characteristics of children placed on INH prophylaxis
Characteristics n (%)
Age at recruitment, years, median [IQR] 2.3 [1.3–3.4]
Weight at recruitment, kg, median [IQR] 11.3 [9–13.3]
Females 167 (50.9)
TST result
 Negative (10 mm) 265 (80.8)
Ethnicity
 Mandinka 155 (47.3)
 Fula 58 (17.7)
 Jola 59 (18.0)
 Wolof 27 (8.2)
 Other 29 (8.8)
Relationship to index case
 Child 108 (33.2)
 Sibling 18 (5.5)
 Other* 166 (51.1)
 Not related 33 (10.2)
* Includes cousin, nephew, niece or other extended family member.
INH = isoniazid; IQR = interquartile range; TST = tuberculin skin test.
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months.9 More site-specific research is required to identify the 
best locally applicable approach to optimise adherence.23
The understanding and willingness shown by carers, especially 
mothers, to administer IPT provides a potential solid base for pro-
grammatic home-delivered IPT. As the project is now being trans-
ferred to the government programme, the priority is to enable 
sustained delivery of INH to homes of child contacts. In the cur-
rent organisation of the health system in The Gambia, commu-
nity health workers and assistants living within the communities 
play a major role in public health. It is intended to provide train-
ing for this group to deliver IPT—and monitor IPT delivery—to 
homes of contacts at minimal or no additional cost to the NTP, as 
they are already involved as TB treatment supporters to the index 
cases.
The use of IsoScreen enabled us to objectively assess whether 
pill counts are a reliable way to assess adherence in The Gambia, 
and we found excellent agreement. Our results should be inter-
preted with caution, however, as some of the negative test results 
came from individuals with good adherence by pill count but 
who had missed doses only in the most recent days. The sensitiv-
ity of the IsoScreen test decreases with the passage of time from 
ingestion of the medication.24 Similarly, some poorly adherent in-
dividuals may have taken IPT prior to their IsoScreen test. As the 
day for IsoScreen testing was not announced in advance, how-
ever, it is unlikely that differential bias was introduced. A negative 
IsoScreen result has been reported in fast acetylators;25 we did not 
assess acetylator status.
In summary, the uptake of and adherence to IPT in our study 
were high by international standards, suggesting that system 
rather than patient factors will be the main determinants of suc-
cess when IPT management is transferred to be fully operational 
under the NLTP. IPT was highly acceptable to care givers and 
children in The Gambia, and home delivery will present an op-
portunity for health education on TB and other topics of public 
health importance, such as malnutrition, sanitation and oral re-
hydration. Training of health workers in childhood TB and IPT 
will be required to ensure success.26,27 The cascade of care sum-
mary showed that there are opportunities for improvement for 
the IPT programme to have maximal public health impact. Fur-
ther studies could explore the reasons why some households do 
not uptake IPT and whether an intervention to reduce care giver 
forgetfulness, such as cell phone text reminders,28 could be 
beneficial.
TABLE 2 Adherence to INH prophylaxis determined by monthly pill count
Month 
Patients on IPT at 
end of month
(N = 328)
n
Good 
adherence
n (%)
Reasonable 
adherence
n (%)
Poor 
adherence
n (%)
1 323 246 (76.2) 49 (15.2) 28 (8.8)
2 316 245 (77.5) 49 (15.5) 22 (6.9)
3 316 245 (77.5) 53 (16.8) 18 (5.7)
4 302 235 (77.8) 51 (16.9) 16 (5.3)
5 311 252 (81.0) 52 (16.7) 7 (2.3)
6 310 259 (83.6) 36 (11.6) 15 (4.8)
INH = isoniazid; ITP = isoniazid preventive therapy.
FIGURE 2 Cascade of care of child contacts eligible for IPT. IPT = 
isoniazid preventive therapy.
TABLE 3 Adherence by pill count and urine test result in the 
IsoScreen™ cohort
Month of 
prophylaxis*
Adherence 
category
Patients
N (%)
Positive IsoScreen
n/N (%)
1 (n = 120) Good 97 (80.7) 82/97 (85.5)
Reasonable 11 (9.2) 4/11 (36.4)
Poor 12 (10.1) 2/12 (16.7)
2 (n = 141) Good 105 (74.5) 90/105 (85.7)
Reasonable 25 (17.7) 14/25 (56.0)
Poor 11 (7.8) 1/11 (9.1)
3 (n = 134) Good 103 (76.9) 83/103 (80.6)
Reasonable 19 (14.2) 12/19 (63.2)
Poor 12 (8.9) 4/12 (33.3)
4 (n = 107) Good 87 (81.1) 74/87 (85.1)
Reasonable 14 (13.2) 9/14 (64.3)
Poor 6 (5.7) 0/6 (0)
5 (n = 96) Good 75 (78.1) 66/75 (88.0)
Reasonable 16 (16.7) 13/16 (81.3)
Poor 5 (5.2) 0/5 (0)
6 (n = 60) Good 45 (75) 42/45 (93.3)
Reasonable 11 (18.3) 8/11 (72.7)
Poor 4 (6.7) 1/4 (25.0)
* The IsoScreen test was used only during the first 12 months of the study in the 
same children; the number of children willing to give urine declined substantially 
despite the dropout rate remaining very low.
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Contexte  :  Région du Grand Banjul en Gambie.
Objectifs  :  Evaluer la couverture, l’adhésion et l’achèvement du 
traitement parmi des enfants exposés à la tuberculose (TB) en 
Gambie quand le traitement préventif par isoniazide (TPI) est donné 
à domicile.
Schéma  :  Les enfants âgés de 5 ans, contacts d’adultes atteints de 
TB à frottis positif, ont été enrôlés de manière prospective. Après 
dépistage sur les symptômes, test cutané à la tuberculine et 
évaluation clinique quand cela était indiqué, les enfants non malades 
ont été mis sous isoniazide, fourni une fois par mois à domicile. 
L’adhésion a été évaluée par un comptage des comprimés et par un 
test urinaire IsoScreen™.
Résultats  :  Sur 404 contacts âgés de 5 ans, 368 (91,1%) ont été 
invités à bénéficier du TPI, et 328 (89,4%) ont consenti et commencé 
le TPI. Sur ces 328 enfants, 18 (5,5%) ont abandonné et 310 (94,5%) 
sont restés sous TPI jusqu’à la fin du 6e mois. Au total, 255/328 
enfants (77,7% ; IC95% 73,2–82,2) ont achevé les 6 mois de 
traitement avec une bonne adhésion. Le test IsoScreen a été positif 
chez 85,3% (435/510) de tous les tests parmi ceux définis comme 
ayant une bonne adhésion par le comptage des comprimés et chez 
16% (8/50) de ceux définis comme ayant une adhésion médiocre 
(P  0,001). L’analyse de la « cascade des soins » a montré, pour tous 
les enfants contacts, un taux de bonne adhésion d’ensemble de 61%.
Conclusion  :  L’administration à domicile du TPI à des enfants contacts 
d’adultes atteints de TB à frottis positif en Gambie a abouti à une 
bonne couverture et à un bon taux d’adhésion, tous deux vérifiables. 
Ce sont les facteurs de système plutôt que ceux liés au patient qui 
sont susceptibles de déterminer le succès du TPI au niveau national.
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Marco de referencia: La zona del Gran Banjul en Gambia.
Objetivos: Evaluar la aceptación del tratamiento preventivo con 
isoniazida (TPI), su cumplimiento y su compleción por parte de los 
niños expuestos en Gambia, cuando se suministra el tratamiento en 
los hogares.
Método: Se incluyeron en el estudio de manera prospectiva los 
niños menores de 5 años de edad que eran contactos de un adulto 
con diagnóstico de tuberculosis (TB) y baciloscopia positiva. Luego 
de la detección sistemática a partir de los síntomas, se practicaron la 
prueba cutánea de la tuberculina y la evaluación clínica cuando 
estaban indicadas; en caso de ausencia de enfermedad activa se inició 
el tratamiento diario con isoniazida, la cual se suministraba en el 
hogar cada mes. Se evaluó el cumplimiento en función del recuento 
de los comprimidos y la prueba IsoScreen™ en muestras de orina.
Resultados: En los 404 contactos menores de 5 años de edad, se 
ofreció el TPI a 368 niños (91,1%) y 328 lo aceptaron y comenzaron 
a recibirlo (89,4%). De este grupo, 18 niños abandonaron el 
tratamiento (5,5%) y 310 recibían aun el medicamento al final del 6 
mes (94,5%). De los 328 niños, 255 terminaron los 6 meses de 
tratamiento, con un cumplimiento satisfactorio (77,7%; IC del 95% 
de 73,2 hasta 82,2). La prueba IsoScreen fue positiva en el 85,3% 
(435/510) de los casos definidos con cumplimiento adecuado según 
el recuento de comprimidos y en el 16% (8/50) de los casos cuyo 
cumplimiento se consideró deficiente (P  0,001). El análisis de la 
trayectoria asistencial reveló que en todos los contactos la tasa global 
de compleción con cumplimiento satisfactorio fue 61%.
Conclusión: El TPI suministrado en el hogar a los niños que son 
contactos de un adulto con diagnóstico de TB y baciloscopia positiva 
alcanza altas tasas de aceptación y de cumplimiento que se pueden 
verificar. Los factores que determinan el éxito del TPI a escala nacional 
dependen del sistema de salud y no del paciente.  
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